ZNTL Zentalis Pharmaceuticals, Inc.

MIXED Impact: 4/10 Institutional Cluster
Horizon weeks Processed 3d 11h ago
Institutional cluster: 3 buyers, 2 sellers (mixed)

Executive Summary

Institutional cluster for ZNTL in Q3 2024 reveals a mixed picture: D.E. Shaw doubled its position to $4.2M and Balyasny added, while Citadel trimmed 40% of its large $18.4M stake and Legal & General nearly exited. Net outflow of ~$5.2M from tracked institutions, but the active manager buying (D.E. Shaw, Balyasny) suggests some conviction ahead of upcoming catalysts.

Key Financial Metrics

Direction
distributing
Buy Value
$4.6M
Sell Value
$18.6M
Net Flow
-$5.2M

Institutional Positions

Net institutional flow: -$5.2M

▲ Buyers (3)

InstitutionActionChangePosition ValueValue Δ
D.E. Shaw DOUBLED +369.6% $4.2M $3.2M
Voya Investment Management DOUBLED +159.6% $184.0K $105.0K
Balyasny Asset Management ADD +70.8% $253.0K $88.0K

▼ Sellers (2)

InstitutionActionChangePrev ValueValue Δ
Citadel TRIM -39.6% $18.4M -$8.4M
Legal & General Group NEAR_EXIT -90.7% $218.0K -$199.9K

Actionable Insight

The divergence between D.E. Shaw (accumulating) and Citadel (reducing) signals high uncertainty around ZNTL's pipeline milestones. With 60% analyst bullishness but 13F lag, traders should watch for upcoming clinical data readouts as the next catalyst to resolve the directional debate.

Key Facts

  • 3 institutions accumulated $4.6M (net +$3.4M) while 2 institutions sold $8.6M net
  • D.E. Shaw (quant) DOUBLED its stake to 1.13M shares worth $4.2M, a $3.2M increase
  • Citadel (quant) trimmed 39.6% of its position, selling ~1.79M shares worth $8.4M
  • Balyasny Asset Management added 70.8% to its position, now 68.7K shares
  • Legal & General Group (passive) nearly fully exited, reducing from $218K to $18K
  • Net dollar flow: sellers outsize buyers $8.6M to $3.4M

Financial Impact

Net institutional outflow of ~$5.2M, driven by Citadel's $8.4M reduction partially offset by D.E. Shaw's $3.2M accumulation

institutional ownershipfloat turnover

Risk Factors

  • 13F data reflects quarter-end positions with a 45-day lag; cluster may have been unwound
  • Clinical-stage biotech binary risk from pipeline failures
  • Historical long calls on ZNTL have underperformed at T+20 (20% win rate)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (15 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ZNTL-2024-Q3
11 reports for ZNTL
Performance horizon
14% Hit rate 1 of 7 directional calls best @ T+1▲ +49.55%Apr 9, 2026
Filters
Rows
Reports for ZNTL — sortable, filterable
Type Now
Jun 11, 2026
3d ago
Institutional Cluster
MIXED ★ 4/10
$3.51 awaiting T+1awaiting T+1
Jun 1, 2026
13d ago
Press Release
NEUTRAL ★ 2/10
$3.95 $3.72▼ −5.82%▼ −5.10%
May 21, 2026
24d ago
Press Release
BULLISH ★ 6/10
$4.06 $3.96▼ −2.46%▼ −3.05%
May 21, 2026
24d ago
8-K
BULLISH ★ 6/10
$4.06 $3.96▼ −2.46%▼ −3.05%
May 12, 2026
4w ago
8-K
BULLISH ★ 7/10
$4.28 $4.28· 0.00%▲ +0.00%
May 12, 2026
4w ago
Press Release
BULLISH ★ 7/10
$4.28 $4.28· 0.00%▲ +0.00%
Apr 21, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$3.99 $3.84▼ −3.76%▼ −4.78%
Apr 17, 2026
8w ago
Press Release
BULLISH ★ 7/10
$4.64 $4.03▼ −13.15%▼ −12.95%
Apr 17, 2026
8w ago
8-K
BULLISH ★ 7/10
$4.64 $4.03▼ −13.15%▼ −12.95%
Apr 9, 2026
9w ago
8-K
BULLISH ★ 7/10
$4.42 $6.61▲ +49.55%▲ +49.61%
Showing 10 of 11

US Market Status

Market Closed — Opens in 5h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access